Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability
Danish Firm Hoping For More From Migraine Drug
Executive Summary
Sales for the migraine product were lower in Q4 than consensus forecasts projected, but reduced costs have pushed yearly earnings beyond expectations.
You may also be interested in...
The Bipolar Big Three: LAIs, Atypical Antipsychotics And Symptom Specific Drugs
Despite the highly genericized nature of the bipolar disorder market, firms have innovated with long-acting injectables, improved atypical antipsychotics and drugs targeting specific symptoms.
Vyepti Sales Disappoint But Lundbeck Sees Growth From Expanded Infusion Center Network
Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.
Lundbeck Set For 'Transformative' Eptinezumab Launch
The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.